Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
Date:7/30/2008

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the second quarter ended June 30, 2008.

"The first half of 2008 has been a remarkably productive time at Anadys," said Steve Worland, Ph.D., President and CEO. "Through the focused efforts of our employees, we have initiated dosing in three clinical programs in six months. For hepatitis C, we commenced dosing in our Phase I clinical trial of ANA598 during the second quarter, and are happy to announce today that we have now commenced dosing in our Phase I clinical trial of ANA773 for HCV. We also continue to enroll patients in our ongoing clinical trial of ANA773 for oncology. We are proud of our progress to date and look forward to achieving additional clinical milestones in the coming months."

Financial Results

As of June 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $42.1 million.

During the second quarter of 2008 the Company had no revenue, compared to $1.3 million for the same quarter of 2007. The revenue in the second quarter of 2007 was primarily derived from the amortization of an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $5.5 million for the second quarter of 2008, compared to $7.0 million for the second quarter of 2007. The $1.5 million decrease primarily resulted from cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs. The
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
6. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
7. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 The report ... Dispensing Systems, Packaging and Labeling Systems, Table-top Counters) ... - Global Forecasts & Trends to 2019” analyzes ... opportunities in North America, Europe, Asia-Pacific, and the ... market tables and 30 figures spread through 300 ...
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... million which brings Q3 orders to $5.8 million and provides a ... projects in North America and one in ... to bid new projects at record levels," said Peter Bruijns ... higher at the end of Q3 than they have been for ...
(Date:10/20/2014)... 2014  GenVec, Inc. (NASDAQ: GNVC ) today ... from its board of directors effective on October 24, 2014.  ... served as its chairman from June 2006 to November 2013.  ... Corporate Governance and Audit Committees of the board.  ... of dedicated service to GenVec, and its stockholders," said ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2
... July 8 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (OTC Bulletin ... firm specializing in the manufacture, research, development,marketing ... Dr.,Shuguang Fang, China-Biotics, Chief Technology Officer, has ... China,s 3rd Annual Food Safety Technology Forum,2008 ...
... purchase, distribute US-made bulk API, BATON ... Albemarle Corporation (NYSE: ALB ), a ... and other active pharmaceutical,ingredients (APIs), has signed ... Laboratories Ltd. As per the agreement, effective,immediately, ...
... Board and Management Focused on Near-Term Milestones and Maintain ... ... DIEGO, July 8 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI, OTC: MGIFF), ... requisition for a special meeting of shareholders,for the purpose of ...
Cached Biology Technology:China-Biotics, Inc. to Present at China's 3rd Annual Food Safety Technology Forum 2008 2China-Biotics, Inc. to Present at China's 3rd Annual Food Safety Technology Forum 2008 3Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 3MIGENIX Corporate Update and Requisition of Special Meeting 2MIGENIX Corporate Update and Requisition of Special Meeting 3MIGENIX Corporate Update and Requisition of Special Meeting 4MIGENIX Corporate Update and Requisition of Special Meeting 5MIGENIX Corporate Update and Requisition of Special Meeting 6MIGENIX Corporate Update and Requisition of Special Meeting 7MIGENIX Corporate Update and Requisition of Special Meeting 8
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... German . To ... treating overdoses, doctors are often limited to supportive therapy such ... a combination of drugs involved. So what can be done ... pills? ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical ... this question. "The task was to develop an agent that ...
(Date:10/16/2014)... they are anything but sustainable: environmental damage to ... becoming increasingly evident. Despite their disadvantages, however, monocultures ... as the sole possibility of achieving higher yields ... Schmid, an ecology professor at the University of ... and forestry. After all, a new study carried ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... the possibility that the critically short supply of livers ... "marginal" livers with a substance that protects them from ... report appears in ACS, journal Molecular Pharmaceutics . ... for liver transplants has grown over the years, though ...
... DALLAS June 1, 2011 A drug ... as a therapy for a common form of dementia, ... hydroxamic acid (SAHA) holds promise as a first-generation drug ... (FTD), a progressive, inherited neurodegenerative disease for which there ...
... Virginia Tech,s Advanced Experimental Thermofluid Engineering Research ... professor Pavlos P. Vlachos, professor of mechanical engineering, ... mechanics from the Measurement Science and Technology ... Physics. John J. Charonko, of Blacksburg, ...
Cached Biology News:Cancer drug holds promise as first treatment for common, inherited dementia 2Virginia Tech mechanical engineers win measurement science best paper award 2
...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... Resistant (X/R) Red System consists of ... Activator and X/R Red Buffer. The ... phosphatase to produce red staining that ... Contains:, , Buffer, 100 mL , ...
Human Cell Line Slides...
Biology Products: